What Makes a Compelling Investment Thesis?
October 2026
Alline Akintore
As early-stage venture investors, often when evaluating a company there is hardly any revenue to underwrite, no retention metrics, and little data to base decisions on. Oftentimes, there is a team going after an opportunity and it is up to us to make an argument for why we believe that there is a clear, falsifiable case for why that very company could become large relatively quickly, why this is the time for that to happen, and why this is the team to pull it off. That argument is our thesis.
As we evaluate potential investments, we distill our thinking and learning into a few sentences, culminating in a thesis that connects the dots on what is changing? What does that change make possible? How large could the opportunity become? Why and how is this company positioned to benefit? Do we have any evidence to suggest that we might be right?
Key Ingredients for a compelling early-stage investment thesis:
Ideally, it starts with an insight that isn’t yet consensus. A technology inflection making something possible that wasn’t possible five years ago; changing customer behavior faster than incumbents can adapt; or an important problem running into a constraint. The thesis should identify that change and ask: what earned insight does this team have about the future that the market may still be underestimating?
Underpinning this is the question of why now? Our theses should look to be very specific and point to what has changed to make this market insight ripe for investment: a platform shift, a new regulation, or a cost curve crossing a threshold.
Why this team? Being right about the future isn’t enough. We look for evidence that, given the earned market insight, this team has the right to win. In the early stages the right to win takes different forms, such as a founder who has lived the problem, has unfair access to customers and understands the customer unusually well; it can be proprietary tech/IP or know-how; it can also be a non-consensus business model that could work for well-understood reasons; and sometimes it is a team’s exceptional ability to outlearn and outexecute everyone else.
Pairing a narrow wedge with a big path. AI may change this to some degree (the jury is still out), but the best early-stage companies are targeting to win decisively in one small defined area or beach head. A sharp wedge includes a specific profile of customer and a well-defined problem. Ultimately, we have to believe that there is a credible path to a large outcome, but we like to see a sharp wedge that we can see expand into adjacent products, customer segments, to mention a few.
A compelling investment thesis articulates how these parts all fit together: the earned insight explains why the timing is right, it’s clear why the team sees it first and is best suited to win, and the wedge shows how they win and scale.
A few examples:
Mueon is rethinking and rebuilding the data center for AI.
OVF investment thesis: AI adoption is pushing data centers past the physical limits of power, heat, and data movement, and the century-old server rack can't be fixed incrementally. Mueon replaces it with Cubelets, modular units that stack compute, memory, power, and cooling together and work with processors from any major architecture. The team, with decades of insights, expertise, and global relationships developed from work at Intel, AMD, Nvidia, Synopsis, and TSMC, is developing novel 3D packaging techniques that could dramatically reduce power consumed while increasing performance.
Backing into our framework:
Earned insight: 3D packaging isn't new, but existing approaches have been held back by heat, yield, and cost. Mueon's insight is that solving those at the system level, not the chip level, unlocks a step change.
Why now: Data centers are expected to use twice today's electricity by 2030, to what is roughly what the entire nation of Japan consumes today. Power has become the binding constraint on AI, and the biggest line in its cost.
Why this team: CEO Wilfred Gomes, CTO Jack Hwang, and colleagues are former Intel Fellows, including the co-inventor of Intel's Foveros 3D packaging architecture. Their technical background and experience are not only incredibly deep and specialized, but scarce as well.
Wedge and path: Because Cubelets work equally with GPU, x86, and Arm processors, Mueon can partner with chipmakers rather than compete with them. The path is a new category in advanced packaging, potentially evolving into a default building block for future AI infrastructure.
Kivo is building compliance software for emerging biotechs.
OVF investment thesis: The number of venture-backed, independent drug developers keeps climbing, yet compliance software is still built and priced for traditional big pharma. Kivo gives these teams one validated platform for regulatory, clinical, and quality work, and is increasingly displacing legacy incumbents in larger accounts. Kivo’s leaders have scaled and sold enterprise SaaS companies before, and know this market from the inside.
Earned secret: Conventional wisdom says that Veeva has life sciences locked up. Kivo saw that the incumbents tailor their products for the requirements of their largest customers - i.e. big pharma, forcing a long tail of more than 1,100 emerging biotechs and device makers to overpay for systems purpose built for someone else. Behind these emerging biotechs sit thousands of sponsors and CROs still running on SharePoint apps and spreadsheets. At a time when new drug design and development is increasingly occurring at venture-backed AI-powered biotechs, Kivo is displacing incumbents with both price & functionality.
Why now: The number of independent life science R&D companies is exploding. Continuous cloud validation is shifting compliance work from the customer to the vendor. AI-driven process automation is the next unlock, widening the gap between modern platforms and legacy systems.
Why this team: CEO Toban Zolman was an early leader in ISI, the pioneer of moving drug submissions from paper to electronic formats, working with tier 1 pharma companies, and has scaled enterprise SaaS to multiple millions in revenue. The team successfully worked together previously, with experience across Veeva, MasterControl, and other industry vendors.
Wedge and path: The wedge is an emerging life science startup, or “sponsor,” buying its first fit-for-purpose documentation and compliance system. The path runs through more modules per customer, packaging for CROs, and replacing legacy systems in larger companies, with the potential to serve a ~$33B market across regulatory, quality, clinical, and document management.
If you know of a founding team with a compelling thesis, and a presence in Oregon and Southern Washington, we’d like to meet with them and see if we can be helpful. Thank you for helping spread the word!
Alline Akintore is a Partner at Oregon Venture Fund and leads the fund’s diligence practice.